Coatomer acts in vaccinia formation. (A) HeLa cells were infected with the WR strain of vaccinia virus for 16 h and then examined by EM with ImmunoGold labeling for β-COP. (Scale bar: 50 nm.) (B) HeLa cells, either treated with siRNA against β-COP for 48 h or mock-treated, were then infected with WR virus for 24 h. The vaccinia replication assay was then performed, with the mean and standard error from 3 experiments shown (P < 0.01). Gel shows the level of β-COP comparing siRNA-treated versus mock-treated HeLa cells. (C) The surface pool of TfR on HeLa cells, either treated with siRNA or mock-treated, was labeled with fluorescently tagged Tf, and then tracked for internalization into early endosomes. (Scale bar: 10 μm.) (D) TZM-bl cells were transfected with siRNAs against different targets, β-COP, CXCR4, Tat, or Luciferase as control, or mock-treated. After infection with HIV-IIIB, β-galactosidase activity was measured, which was expressed as relative light units (RLU), and then normalized to the condition of mock treatment. The mean with standard deviation from 3 experiments is shown. (E) HeLa cells, either treated with siRNA against β-COP for 48 h or mock-treated, were then infected with WR virus for 24 h. Intracellular viral forms were then purified from infected cells, followed by EM examination for intact viruses. Quantitation was performed from 10 randomly selected images, and then expressed as mean with standard error (P < 0.01).